{"id":511,"date":"2023-07-31T08:56:31","date_gmt":"2023-07-31T07:56:31","guid":{"rendered":"https:\/\/seamlesstxdev.wpenginepowered.com\/?page_id=511"},"modified":"2026-01-28T16:44:29","modified_gmt":"2026-01-28T21:44:29","slug":"home","status":"publish","type":"page","link":"https:\/\/seamlesstx.com\/es\/","title":{"rendered":"Inicio"},"content":{"rendered":"
<\/div><\/div>
<\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t

Entregando terapias para transformar la vida de los pacientes a trav\u00e9s de la tecnolog\u00eda de recombinasa<\/h2>\n<\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t
\n \n Navigate to the next section<\/span>\n \n <\/path>\n <\/polyline>\n <\/svg>\n <\/a>\n <\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t
<\/div><\/div><\/div>
\n\t
\n\t\t
<\/div><\/div><\/div>\n\t\t\t
\n\t\t\t\t\n
\n\t
\n\t\t

Accediendo a un enfoque sin fisuras para tratar enfermedades graves<\/h1>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t

Sobre Nosotros<\/h2>\n
\n\t
\n\t\t

We are a team of experienced drug developers dedicated to correcting the genetic cause of disease by making large edits to the human genome using the unparalleled precision<\/strong>\u00a0and\u00a0efficiency<\/strong>\u00a0of programmable recombinases. Seamless Therapeutics is applying programmable recombinase technology to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t

<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\n
\n\t
\n\t\t

Seamless is developing a unique approach to gene editing using programmable recombinases to address genetic disease. Our technology Seamlessly performs large, precise DNA deletions or insertions anywhere in the genome without introducing additional mutations. By unlocking programmable recombinases, Seamless has the potential to transform patient outcomes across a broad range of diseases.<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
<\/div><\/div><\/div>\n\t\t\t
\n\t\t\t\t\n
\n\t
\n\t\t

Our Strategic Focus<\/h1>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t
<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t

Leadership<\/h2>\n
\n\t
\n\t\t

An esteemed and accomplished leadership team drives Seamless Therapeutics. Together with their experienced Board of Directors, they pursue a shared vision to transform the gene-editing landscape.<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>

<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div><\/div>\n
\n\t
\n\t\t

Albert Seymour, PhD<\/strong><\/a>
\nPresident, CEO, & Managing Director<\/p>\n\t<\/div>\n<\/div>\n\n\n\n

\n
\n
\n
\n \n \"LinkedIn\"\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>
<\/div><\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t\n
\n\t
\n\t\t

Albert Seymour<\/strong> serves as the President, Chief Executive Officer, and Managing Director of Seamless Therapeutics and is a member of the Board of Directors. During his distinguished career in human genetics and pharmaceutical research and development, he spearheaded Homology Medicines\u2019 phenylketonuria (PKU) program, from concept to the world\u2019s first gene therapy clinical trial for PKU in under 3 years. Dr Seymour has also held various senior leadership roles at Shire Pharmaceuticals and Pfizer and is a member of the Board of Directors of Ensoma and Iris Medicine. Dr Seymour received his BSc degree in Biology from the University of Delaware and MSc degree in Molecular Biology from Johns Hopkins University and his PhD and post-doctoral training in human genetics at the University of Pittsburgh.<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>

<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t\n
\n\t
\n\t\t

Deborah Kinch<\/strong> oversees R&D, Regulatory\/Quality, CMC\/Technical Operations, and Program Portfolio Management at Seamless Therapeutics. Before joining Seamless Therapeutics, she served as Chief Development Officer at Homology Medicines, where she supported Phase 1\/2-readiness in PKU gene therapy\/editing programs. Prior to Homology, Dr Kinch served as head of the Early Regulatory Sciences group at Biogen. Her experience building and leading high-performing teams and use of cross-functional strategies to advance research into clinical development has led to the clearance of INDs and CTAs for both gene transfer and gene-editing platforms. Dr Kinch holds an AB in Biochemistry from Mount Holyoke College and a PhD in Molecular Biophysics and Biochemistry from Yale University.<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div><\/div>\n
\n\t
\n\t\t

Deborah Kinch, PhD<\/strong><\/a>
\nChief Development Officer<\/p>\n\t<\/div>\n<\/div>\n\n\n\n

\n
\n
\n
\n \n \"LinkedIn\"\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>
<\/div><\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div><\/div>\n
\n\t
\n\t\t

Anne-Kristin Heninger, PhD<\/strong><\/a>
\nHead of Operations & Managing Director, Dresden, Germany<\/p>\n\t<\/div>\n<\/div>\n\n\n\n

\n
\n
\n
\n \n \"LinkedIn\"\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>
<\/div><\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t\n
\n\t
\n\t\t

Anne-Kristin Heninger<\/strong> is a co-founder of Seamless Therapeutics and serves as Head of Operations and Managing Director in Germany. Dr Heninger played a key role in developing the business and financial strategies for Seamless Therapeutics, while also successfully securing IP rights for the company. Dr Heninger began her work in genome editing at the Max-Planck-Institute of Molecular Cell Biology and Genetics in Dresden. She holds a BSc in Biochemistry and Microbiology from the University of Washington in Seattle and earned her PhD in Immunology at the Dresden University of Technology.<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>

<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t\n
\n\t
\n\t\t

Felix Lansing<\/strong> is a scientific co-founder and currently serves as the Chief Technology Officer. The foundation of the technology used at Seamless originated from Dr Lansing\u2019s research and discovery of programmable recombinases during his PhD studies at Dresden University of Technology. He is an author of many peer-reviewed publications, an inventor on 7 patents, and is dedicated to leveraging his expertise to address how programmable recombinases can be applied to solve genetic disease and improve the lives of patients. He earned his BSc in Molecular Biology from Bielefeld University, his MSc in Regenerative Biology and Medicine and his PhD in genetics and genome engineering at the Dresden University of Technology.<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div><\/div>\n
\n\t
\n\t\t

Felix Lansing, PhD<\/strong><\/a>
\nCo-Founder & CTO<\/p>\n\t<\/div>\n<\/div>\n\n\n\n

\n
\n
\n
\n \n \"LinkedIn\"\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>
<\/div><\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>
\n \n Navigate to the next section<\/span>\n \n <\/path>\n <\/polyline>\n <\/svg>\n <\/a>\n <\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t
<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div>

Board of Directors<\/h2>
<\/div><\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div><\/div>\n
\n\t
\n\t\t

Albert Seymour, PhD<\/strong><\/a>
\nPresident, CEO, & Managing Director<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div><\/div>\n
\n\t
\n\t\t

Adam Rosenberg<\/strong><\/a>
\nChairman<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div><\/div>\n
\n\t
\n\t\t

Dmitrij Hristodorov, PhD<\/strong><\/a>
\nBoard Director<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div><\/div>\n
\n\t
\n\t\t

Varun Gupta, PhD<\/b><\/a>
\nBoard Director<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div><\/div>\n
\n\t
\n\t\t

Alvin Shih, MD<\/b><\/a>
\nBoard Director<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t

<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div>

Scientific Advisory Board<\/h2>
<\/div><\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div><\/div>\n
\n\t
\n\t\t

Prof. Frank Buchholz, PhD<\/strong><\/a>
\nChair of Scientific Advisory Board<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div><\/div>\n
\n\t
\n\t\t

Prof. Beverly Davidson, PhD<\/a>
\n<\/b>Member, Scientific Advisory Board<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
\n\t\t
\n\t\t\t
<\/div><\/div><\/div>\n
\n\t
\n\t\t

Prof. Mark Foster, PhD<\/strong><\/a>
\nMember, Scientific Advisory Board<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t

<\/div><\/div><\/div>
\n\t
\n\t\t
<\/div><\/div>\n\t\t\t
\n\t\t\t\t

Inversores<\/h4>\n
\n\t
\n\t\t

Seamless Therapeutics is supported by leading life-science investors.<\/p>\n\t<\/div>\n<\/div>\n\n\n\n\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
<\/div><\/div>\n\t\t\t
\n\t\t\t\t
\n
\n
\n
\n \n \"\"\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
<\/div><\/div>\n\t\t\t
\n\t\t\t\t
\n
\n
\n
\n \n \"\"\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
<\/div><\/div>\n\t\t\t
\n\t\t\t\t
\n
\n
\n
\n \n \"\"\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
<\/div><\/div>\n\t\t\t
\n\t\t\t\t
\n
\n
\n
\n \n \"\"\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t
<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t

News & Press Releases<\/h2>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t\n
\n\t
\n\t\t

January 28, 2026<\/p>\n\t<\/div>\n<\/div>\n\n\n\n

Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss<\/a><\/h2>
<\/div><\/div>READ MORE<\/span><\/a>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t\n
\n\t
\n\t\t

May 8, 2025<\/p>\n\t<\/div>\n<\/div>\n\n\n\n

Seamless Therapeutics Expands Board of Directors with Appointment of Alvin Shih<\/a><\/h2>
<\/div><\/div>READ MORE<\/span><\/a>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t\n
\n\t
\n\t\t

October 22, 2024<\/p>\n\t<\/div>\n<\/div>\n\n\n\n

Seamless Therapeutics to Present New Data at ESGCT Demonstrating its Ability to Reprogram Large Serine Recombinases to Specific Target Sites in the Human Genome<\/a><\/h2>
<\/div><\/div>READ MORE<\/span><\/a>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>
<\/div><\/div>
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t\n
\n\t
\n\t\t

April 23, 2024<\/p>\n\t<\/div>\n<\/div>\n\n\n\n

Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform<\/a><\/h2>
<\/div><\/div>READ MORE<\/span><\/a>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t
\n\t\t\t\n
\n\t
\n\t\t

March 16, 2023<\/p>\n\t<\/div>\n<\/div>\n\n\n\n

Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases<\/a><\/h2>
<\/div><\/div>READ MORE<\/span><\/a>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t
\n \n Navigate to the next section<\/span>\n \n <\/path>\n <\/polyline>\n <\/svg>\n <\/a>\n <\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t
<\/div><\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t

Related Research<\/h2>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t

Activation of recombinases at specific DNA loci by zinc-finger domain insertions<\/a><\/h2>\n
\n\t
\n\t\t

Nature Biotechnology<\/em>
\n<\/strong>January 31, 2024<\/p>\n\t<\/div>\n<\/div>\n\n\n\nDOWNLOAD<\/span><\/a>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
\n\t\t
\n\t\t\t

Quantification of evolved DNA-editing enzymes at scale with DEQSeq<\/a><\/h2>\n
\n\t
\n\t\t

Genome Biology<\/em>
\n<\/strong>November 6, 2023<\/p>\n\t<\/div>\n<\/div>\n\n\n\nDOWNLOAD<\/span><\/a>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
\n\t\t
\n\t\t\t

Discovery and characterization of novel Cre-type tyrosine site-specific recombinases for advanced genome engineering<\/a><\/h2>\n
\n\t
\n\t\t

Nucleic Acids Research<\/strong><\/em>
\nJune 9, 2023<\/p>\n\t<\/div>\n<\/div>\n\n\n\nDOWNLOAD<\/span><\/a>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t

<\/div><\/div><\/div>
\n\t
\n\t\t
<\/div><\/div>\n\t\t\t
\n\t\t\t\t
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t

Carreras<\/h2>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t\n
\n\t
\n\t\t

We are a dynamic team pioneering a groundbreaking new gene-editing approach with a deep understanding of recombinases and their potential in repairing genes that cause serious diseases. We foster creativity, leadership, and teamwork, and empower our people to make decisions and contribute positively to our goals. We also offer a supportive environment for colleagues to learn from each other, tackle challenges together, and celebrate our achievements.<\/p>\n\t<\/div>\n<\/div>\n\n\n\nGO TO CAREER PAGE<\/span><\/a>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n\n\t

\n\t\t
<\/div><\/div><\/div>\n\t\t\t
\n\t\t\t\t\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t
<\/div><\/div>
<\/div><\/div>
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t
<\/div> <\/div>
\n\t
\n\t\t
\n\t\t
\n\t\t\t

We\u2019re not currently hiring, but we\u2019re always happy to connect with talented people. Feel free to check back soon or connect with us on LinkedIn<\/a><\/p>\n

careers@seamlesstx.com<\/a><\/p>\n<\/div>\n\t\t<\/div> \n\t<\/div>\n\t<\/div> \n<\/div><\/div>\n\t\t\t<\/div> \n\t\t<\/div>\n\t<\/div> \n<\/div><\/div>","protected":false},"excerpt":{"rendered":"Delivering therapies to transform the lives of patients through recombinase technology Navigate to the next section Accessing a seamless approach to treating severe disease About Us We are a team...","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-511","page","type-page","status-publish"],"yoast_head":"\nHome - Seamless Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/seamlesstx.com\/es\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Home - Seamless Therapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"23 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/seamlesstx.com\\\/\",\"url\":\"https:\\\/\\\/seamlesstx.com\\\/\",\"name\":\"Home - Seamless Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlesstx.com\\\/#website\"},\"datePublished\":\"2023-07-31T07:56:31+00:00\",\"dateModified\":\"2026-01-28T21:44:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/seamlesstx.com\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/seamlesstx.com\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/seamlesstx.com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/seamlesstx.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Home\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/seamlesstx.com\\\/#website\",\"url\":\"https:\\\/\\\/seamlesstx.com\\\/\",\"name\":\"Seamless Therapeutics\",\"description\":\"Overcoming the boundaries of gene editing by unlocking the full potential of recombinases.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/seamlesstx.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Home - Seamless Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/seamlesstx.com\/es\/","twitter_card":"summary_large_image","twitter_title":"Home - Seamless Therapeutics","twitter_misc":{"Est. reading time":"23 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/seamlesstx.com\/","url":"https:\/\/seamlesstx.com\/","name":"Home - Seamless Therapeutics","isPartOf":{"@id":"https:\/\/seamlesstx.com\/#website"},"datePublished":"2023-07-31T07:56:31+00:00","dateModified":"2026-01-28T21:44:29+00:00","breadcrumb":{"@id":"https:\/\/seamlesstx.com\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/seamlesstx.com\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/seamlesstx.com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/seamlesstx.com\/"},{"@type":"ListItem","position":2,"name":"Home"}]},{"@type":"WebSite","@id":"https:\/\/seamlesstx.com\/#website","url":"https:\/\/seamlesstx.com\/","name":"Seamless Therapeutics","description":"Overcoming the boundaries of gene editing by unlocking the full potential of recombinases.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/seamlesstx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"_links":{"self":[{"href":"https:\/\/seamlesstx.com\/es\/wp-json\/wp\/v2\/pages\/511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seamlesstx.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/seamlesstx.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/seamlesstx.com\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/seamlesstx.com\/es\/wp-json\/wp\/v2\/comments?post=511"}],"version-history":[{"count":0,"href":"https:\/\/seamlesstx.com\/es\/wp-json\/wp\/v2\/pages\/511\/revisions"}],"wp:attachment":[{"href":"https:\/\/seamlesstx.com\/es\/wp-json\/wp\/v2\/media?parent=511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}